Physician profile
Punit Parasher
NPI 1316926579
$14,176.98
in general payments reported to CMS, 2019-2025
33 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,048 · 2020: $555 · 2021: $489 · 2022: $1,044 · 2023: $1,476 · 2024: $1,336 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,040.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $7,397.35 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $1,408.59 | 2019-2025 | |
| Amgen INC. | $650.46 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $516.64 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $458.25 | 2019-2025 | Jardiance |
| Abbott Laboratories | $452.78 | 2019-2024 | Cardiomems, Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $419.17 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $352.42 | 2019-2024 | Eliquis, Camzyos |
| Medtronic, INC. | $305.07 | 2023 | Azure Xt Dr Mri Surescan, Corevalve Evolut R |
| Astrazeneca Pharmaceuticals Lp | $248.66 | 2020-2024 | Farxiga, Brilinta |
| Bardy Diagnostics, INC. | $205.00 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $204.95 | 2023-2025 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $203.42 | 2022-2023 | Optimizer |
| Janssen Pharmaceuticals, INC | $178.94 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $157.02 | 2021-2024 | Opsumit, Uptravi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $155.90 | 2023-2024 | Inpefa |
| Pfizer INC. | $155.33 | 2020-2025 | |
| Cleerly, INC. | $118.57 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Alnylam Pharmaceuticals INC. | $118.33 | 2022-2024 | Amvuttra |
| Baxter Healthcare | $76.98 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $64.54 | 2019-2023 | |
| Boston Scientific Corporation | $56.13 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $45.30 | 2024 | Arcalyst |
| Philips North America LLC | $39.23 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.27 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $32.72 | 2019 | |
| Daiichi Sankyo INC. | $26.25 | 2023 | Injectafer |
| Recor Medical INC | $21.95 | 2024 | Paradise Renal Denervation System |
| Astellas Pharma US INC | $19.03 | 2021 | |
| Amarin Pharma, INC. | $16.18 | 2021 | |
| Lilly USA, LLC | $13.65 | 2025 | Zepbound |
| Kowa Pharmaceuticals America, INC. | $11.30 | 2021 | |
| Vivaquant INC, Dba Rhythm Express | $8.60 | 2024 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Punit Parasher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.